Boston-based Platelet BioGenesis provides received $10 million in Series A financing to relocate their platelet manufacturing technology forward. The financing circular for the Harvard University spinout was led by Qiming U. S. Healthcare Fund and included Vivo Funds, eCoast Angels and other investors.
The new funding will support preclinical studies for Platelet BioGenesis’ come cell-based bioreactors. The company hopes to begin clinical trials within around three years. By removing human donations from the platelet equation, Platelet Biogenesis hopes to create a more reliable provide.
“ We can only store platelets pertaining to five days, so we can’ t always get them whenever we need them, ” said Cofounder and Chief Company Officer Sven Karlsson in a phone interview. “ The main cause of the problem is our dependence on human donors. ”
Platelet supply is highly reliant on consistent bloodstream donations. However , during summer vacations, inclement weather or various other events, donations can decline. On the other side of the ledger, terrorist attacks or natural disasters can increase demand whilst donations remain static.
“ By production platelets, we extend shelf life, eliminate the need for microbial and viral screening, make them more affordable and produce all of them on demand, ” said Karlsson.
The particular company’ s bioreactor is designed to act like bone marrow, making use of induced pluripotent stem (iPS) cells to generate megakaryocytes (bone marrow cells that only produce platelets). The megakaryocytes are placed in the top portion of the reactor and bathed in a medium. Platelets transfuse through a porous membrane plus collect in the bottom. Because megakaryocytes can be frozen, they could be easily stockpiled and thawed to meet increased demand.
“ In the U. S., we would produce platelets in centralized manufacturing facilities and distribute them with the traditional supply chain, ” said Karlsson. “ The hospital today might order a bag of platelets from the Red Cross. In the future, they might order a handbag from us. ”
Bioreactors could also be used to disaster areas or war zones as required, ensuring adequate platelet supplies.
Manufactured platelets could especially benefit trauma and chemotherapy patients, each of which can experience treatment delays during platelet disadvantages. Karlsson believes the market is around $2 billion in the Oughout. S. and between five and ten times that will worldwide. There are many areas where platelet transfusions are scarce or even nonexistent.
“ Platelets today are really restricted to first world countries and within major cities, ” said Karlsson. “ If you go into rural America, it could be very hard to access platelet transfusions. By potentially increasing the particular shelf life and eliminating the connection to human contributor, we should be able to extend platelet transfusion to billions of individuals around the world who need them. ”